RGNX – regenxbio inc. (US:NASDAQ)
Stock Stats
News
11/21
08:05 am
rgnx
Medium
REGENXBIO Inc. (NASDAQ: RGNX) had its price target lowered by analysts at HC Wainwright from $40.00 to $36.00. They now have a "buy" rating on the stock.
11/20
08:07 am
rgnx
Low
REGENXBIO Inc. (NASDAQ: RGNX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $52.00 price target on the stock.
11/18
07:08 am
rgnx
Medium
REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA [Yahoo! Finance]
11/18
07:05 am
rgnx
Low
REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA
11/15
08:03 am
rgnx
High
REGENXBIO Inc. (NASDAQ: RGNX) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $22.00 price target on the stock.
11/6/2024
04:05 pm
RGNX
18.7%
MISS
8/1/2024
04:05 pm
RGNX
-2.0%
BEAT
5/8/2024
04:05 pm
RGNX
-5.9%
MISS
2/27/2024
04:05 pm
RGNX
-0.5%
MISS
11/20
08:07 am
Reiterates
Buy
Buy
Chardan Capital
Low
0.7%
11/20
05:59 am
Maintains
Buy
Buy
Chardan Capital
Medium
-3.1%
11/15
08:03 am
Reiterates
Overweight
Morgan Stanley
High
-19.2%
11/15
08:03 am
Reiterates
Overweight
Morgan Stanley
High
-19.2%
11/15
07:03 am
Assumes
Overweight
Morgan Stanley
High
-19.3%
11/14
09:01 pm
rgnx
High
Form SC 13G/A REGENXBIO Inc. Filed by: Redmile Group, LLC
11/12
04:48 pm
rgnx
Low
Form SC 13G/A REGENXBIO Inc. Filed by: VANGUARD GROUP INC
11/6
04:17 pm
rgnx
High
Form 10-Q REGENXBIO Inc. For: Sep 30
11/6
04:10 pm
rgnx
High
Form 8-K REGENXBIO Inc. For: Nov 06
11/4
01:50 pm
rgnx
Low
Form SC 13G/A REGENXBIO Inc. Filed by: VANGUARD GROUP INC
Show more
Top News Gainers
3/19 Regenxbio Inc (NASDAQ: RGNX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 12.1%
4/8 Form DEF 14A REGENXBIO Inc. For: May 29 8.8%
10/15 Form 8-K REGENXBIO Inc. For: Oct 11 8.8%
1/15 Regenxbio Inc (NASDAQ: RGNX) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. 7.1%
11/6 The FDA Paused This Biotech's Gene Therapy Study — And Shares Tumbled [Investor's Business Daily] 6.9%
8/28 REGENXBIO to Present at Upcoming Investor Conferences 5.4%
4/22 REGENXBIO Announces Additional Positive Long-term and Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD 5.0%
12/12 We Think REGENXBIO (NASDAQ:RGNX) Can Afford To Drive Business Growth [Yahoo! Finance News] 4.8%
7/17 Regenxbio Inc (NASDAQ: RGNX) was given a new $84.00 price target on by analysts at Morgan Stanley. They now have a "buy" rating on the stock. 4.4%
1/9 REGENXBIO Reports Continued Progress Across Programs in Year-End 2019 Corporate Update 4.2%
Top News Decliners
3/11 Regenxbio Inc (NASDAQ: RGNX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -17.1%
2/26 Form 8-K REGENXBIO Inc. For: Feb 26 -14.8%
10/30 Regenxbio's Wet AMD Data Is Encouraging, With Majority Of Patients Free Of Rescue Injections [Seeking Alpha] -12.0%
10/11 Big Pharma Has Mad Love For These 2 Biotechs [The Motley Fool] -11.9%
3/6 Form SC 13G REGENXBIO Inc. Filed by: GIC Private Ltd -10.2%
3/31 REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder -10.0%
5/30 REGENXBIO Announces Completion of Dosing for Phase I/IIa Clinical Trial of RGX-314 in Wet AMD -9.9%
5/7 Q1/2019 3/31/2019 EPS -0.890 ZacksConsensus -0.850 ActVsEst (0.040) - Miss -8.5%
4/30 REGENXBIO To Host Conference Call on May 7 to Discuss First Quarter 2020 Financial Results and Recent Operational Highlights -8.4%
8/8 Regenxbio Inc (NASDAQ: RGNX) was given a new $79.00 price target on by analysts at Evercore ISI. They now have a "buy" rating on the stock. -6.2%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3